Whistleblower exposes multiple issues with Pfizer’s Covid-19 vaccine trial https://www.rt.com/usa/539247-whistleblower-issues-pfizer-trial/ By Kit Klarenberg, an investigative journalist exploring the role of intelligence services in shaping politics and perceptions.
3 Nov, 2021
Leading medical journal The BMJ has published an incendiary report exposing faked data, blind trial failures, poorly trained vaccinators, and a slow follow-up on adverse reactions in the phase-three trial of Pfizer’s Covid jab.
Central to the exposé is Brook Jackson, who, for two weeks, served as regional director at Ventavia Research Group, the company contracted to assist with the pivotal trial. She provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails supporting her concerns.
Pfizer Whistleblower Reveals Why She Finally Decided to Come Forward Landon Mion https://townhall.com/tipsheet/landonmion/2021/10/15/pfizer-whistleblower-reveals-why-she-finally-decided-to-come-forward-n2597536 Oct 15, 2021
Company That Managed Pfizer Vaccine Trial Sites ‘Falsified Data’: Whistleblower https://science.thewire.in/the-sciences/company-that-managed-pfizer-vaccine-trial-sites-falsified-data-whistleblower/
03/11/2021
Ventavia, a subcontractor for Pfizer’s COVID-19 vaccine phase 3 clinical trial, allegedly falsified data, unblinded patients and was slow to follow up on adverse events.
Brook Jackson reportedly brought these problems up with her superiors – but was fired shortly after she emailed a complaint to the US Food and Drug Administration.
The FDA didn’t follow up on Jackson’s complaint – and Pfizer, which has known of the problems at Ventavia, has hired the company for four more trials.
Brook Jackson, a regional director who was employed by Ventavia Research Group, told British Medical Journal that the company “falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events” reported in the pivotal phase III trial of the Pfizer-BioNTech vaccine.
Despite Jackson repeatedly notifying Ventavia of the problems, the company reportedly took no corrective action. This prompted Jackson to send a complaint by email to the US Food and Drug Administration (FDA) – the country’s top regulatory body – in September 2020. But less than 24 hours later, Ventavia fired her in an apparent reprisal.
I